Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.18

-1.4%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jayhawk969 who wrote (22932)	7/8/1998 4:58:00 PM
From: Henry Niman	Read Replies (1) of 32384

JD, One of the big areas of interest to LGND is SERMs. A meeting on osteoporosis is coming up and LGND's partners (PFE, AHP & LLY) will be presenting. The LLY program with LGND involves combining Rexinoids with SERMs. Here's what LLY will say about one of its 2nd generation SERMs (Raloxifene is Evista): Comparison between Raloxifene and LY353381 Henry U. Bryant, Ph.D., Preclinical Pharmacologist, Skeletal Diseases Research, Lilly Research Laboratories Raloxifene, a selective estrogen receptor modulator (SERM) was recently approved as an alternative to estrogen for prevention of osteoporosis without the reproductive tissue side effects or risks associated with estrogen itself. Intense research activity in the area of SERMs has led to a number of new and interesting compounds which are currently in clinical development. One such compound, LY353381*HCL is a superior estrogen antagonist with respect to blocking estrogen effect on the uterus and preventing carcinogen induced breast cancer in a rat model.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next